Alpha Layer / Signal Explorer

Signal Explorer

10-K · 10-Q · 8-K · last 6 months · ← back to feed

Clear ×
Spyre Therapeutics, Inc. SYRE

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Apr 16, 2026 8-K 4 signals fired
Other
Ipo Net Proceeds Disclosure Sanctions Compliance Representation Form S3 Shelf Registration Disclosure Ipo Or Capital Raising Completion
Apr 13, 2026 8-K 6 signals fired
Core
Secondary Endpoint Mentioned Clinical Trial Result
Other
Patient Retention High Interim Data Positive Kol Endorsement Enrollment Ahead Of Schedule
Apr 13, 2026 8-K 1 signal fired
Other
Auditor Appointment Ratification
Feb 19, 2026 10-K 60 signals fired · top 15
Other
Cybersecurity Breach Reputational Harm Disclosure Nol Carryforward Expiration Disclosure Nol Tax Credit Carryforward Net Loss Reported Cash Flow Statement Investing Activities Reimbursement Price Pressure Risk Restructuring Charge Disclosed Cybersecurity Risk Management Program Disclosure Enrollment Ahead Of Schedule Patent Family Portfolio Disclosure Ipo Or Capital Raising Completion Financing Activities Cash Flow Disclosure Public Float Disclosure
Core
Regulatory Designation Only Secondary Endpoint Mentioned
Feb 19, 2026 8-K 14 signals fired
Other
Net Loss Reported Ipo Or Capital Raising Completion Kol Endorsement Interim Data Positive Operating Margin Declining Publication Positive Enrollment Ahead Of Schedule Ipo Net Proceeds Disclosure
Core
Indication Expansion Clinical Trial Result Lead Asset Progress Patient Enrollment Velocity
Healthcare
Utilization Declining Services
Business Services
Demand Softening
Jan 12, 2026 8-K 17 signals fired · top 15
Other
Executive Educational Background Disclosure Enrollment Ahead Of Schedule Board Committee Member Listing Publication Positive Safety Differentiated Interim Data Positive Checkpoint Inhibitor Program Patient Retention High Fast Track Granted Fda Aligned
Core
Clinical Trial Result Combination Therapy Mentioned Secondary Endpoint Mentioned
Biotech Risk
Accelerated Approval
Biotech v3
Ai Drug Discovery Investment
Nov 4, 2025 10-Q 29 signals fired · top 15
Other
Enrollment Ahead Of Schedule Form S3 Shelf Registration Disclosure Segment Aggregation Disclosure Fair Value Hierarchy Disclosure Cash Flow Statement Investing Activities Interim Data Positive Financing Activities Cash Flow Disclosure Net Loss Reported Ipo Or Capital Raising Completion Material Weakness In Internal Controls Disclosed Fda Aligned Equity Plan Share Reserve Disclosure Shares Outstanding Disclosure
Core
Combination Therapy Mentioned Clinical Trial Result
Nov 4, 2025 8-K 18 signals fired · top 15
Other
Net Loss Reported Revenue Increase Attribution Disclosure Interim Data Positive Patient Retention High Kol Endorsement Other Income Expense Disclosure Enrollment Ahead Of Schedule Fda Aligned Publication Positive Safety Differentiated Expanded Access Program Active
Core
Clinical Trial Result Lead Asset Progress Combination Therapy Mentioned Indication Expansion